Director/PDMR Shareholding
Faron Pharmaceuticals Ltd. announced that its Non-Executive Chairman, Tuomo Pätsi, subscribed for 400,002 ordinary shares at €0.5 per share on March 30, 2026, as part of the company's rights issue. This transaction represents a direct investment by a key insider, demonstrating confidence in the company's ongoing development and its lead immunotherapy asset, bexmarilimab. The subscription, totaling €200,001, was conducted on the Nasdaq First North Growth Market.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | March 31, 2026 at 09:00:00 EEST |
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Tuomo Pätsi, Non-Executive Chairman of the Company, subscribed 400,002 ordinary shares in Faron at price of €0.5 per share on 30 March 2026, pursuant to the Rights Issue announced by the Company on 10 March 2026.
Further details are set out in the Notification of Dealing Form below.
| a. | Name | Tuomo Pätsi |
| 2 | Reason for notification | |
| a. | Position/Status | Non-Executive Chairman |
| b. | Initial notification/ Amendment | Initial Notification |
| a. | Name | Faron Pharmaceuticals Ltd. |
| b. | LEI | 7437009H31TO1DC0EB42 |
| a. | Description of the financial instrument, type of instrument Identification Code | Subscription for new ordinary shares, pursuant to a rights issue ISIN: FI4000153309 |
| b. | Nature of the transaction | Subscription |
| Price(s) per share (p) | Volume(s) | |
| EUR 0.5 | 400,002 | |
| d. | Aggregated information Volume Price | Transaction details (a) (1): Volume 400,002 Unit price: 0.5 EUR |
| f. | Place of the transaction | Nasdaq First North Growth Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.